Navigating an Increasingly Complex Treatment Paradigm in the Management of HIV: Individualized Therapy for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Merck Sharp & Dohme Corp. and ViiV Healthcare

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 persons in the United States aged 13 years and older are living with HIV infection. Additionally, an estimated 6,955 people died from HIV and AIDS in 2018. Fortunately for patients with HIV, several new therapies have become available over the past few years, and more are set to become available soon.

Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare professionals. HIV treatment focuses on controlling the disease and living longer, healthier lives. Antiretroviral therapy (ART) is the use of HIV medicines to treat HIV infection. ART has evolved considerably over the past three decades. With many antiretroviral drugs, combinations, and classes available, health care providers have multiple choices regarding ART. While these choices provide clinicians with many useful options, they also lead to challenges. One of the biggest challenges for clinicians is individualizing the care of HIV-positive patients and understanding when certain ART therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ART must be tailored to the individual patient and his or her abilities and diverse needs. Fortunately, new treatments have become available over the past couple of years offering physicians additional options to address the unmet needs of these HIV patients, including combination regimens. Additionally, more agents and combinations are now available for heavily pretreated patients. Options for HIV prevention and treatment continue to expand at a rapid pace. To improve outcomes for patients, clinicians working in healthcare settings must keep current with the latest treatments, guideline recommendations, strategies for individualizing therapy, and best practices for coordinating care and specialty referral.

Upon completion of this activity, participants will be able to:

  • Discuss the clinical and economic burden of HIV, including factors that contribute to poor prognosis and increased costs

  • Explore recent clinical trial data to identify appropriate patient populations for new and emerging 2-drug regimens, including long-acting ART

  • Examine the role of newer therapies for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection

  • Evaluate optimal ART regimens based on patient- or drug-related factors, including age, comorbidities, concomitant medications, potential for ART-related toxicities, adherence, or patient preferences

  • Identify strategies to optimize patient-centered HIV medication therapy management and adherence support

  • Assess the managed care considerations of new and emerging therapies, including combination options and long-acting ART, by exploring where these agents fit in the HIV management paradigm


Faculty: Gary Owens, MD
Gary Owens Associates


Dr. Owens serves on as a consultant for Lilly, ICON, Magnolia Innovation, MCRA, Octave Biosciences, Vertex and Xcenda. His presentation has been peer reviewed for any bias. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Merck Sharp & Dohme Corp. and ViiV Healthcare

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue